Celularity Inc. Deferred Revenue Recognized
Celularity Inc. (CELU) reported Deferred Revenue Recognized of $3.74 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-12-06.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2024-12-06
- Celularity Inc. contract with customer, liability, revenue recognized for the quarter ending 2021-09-30 was $6.75M.
- Celularity Inc. contract with customer, liability, revenue recognized for fiscal 2021 was $2.20M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|
| 2024-09-30 | $3.74M 10-Q · filed 2024-12-06 | ||
| 2023-09-30 | $3.82M 10-Q · filed 2024-12-06 | ||
| 2021-12-31 | $2.20M 10-K · filed 2022-03-31 | ||
| 2021-09-30 | $6.75M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |